SoundHound Inc.’s Houndify Voice AI Powers In-Car Assistant in Honda’s Newest European Models
27.8.2020 11:00:00 EEST | Business Wire | Press release
SoundHound Inc. Ⓡ the leading innovator of voice-enabled AI and conversational intelligence technologies, today announced a milestone in its strategic partnership with Honda Motor Company with the integration of its Houndify voice AI platform into the new Honda e electric car and the top selling Honda Jazz in Europe. The Honda Personal Assistant—powered by Houndify—gives drivers an in-car conversational interface allowing them to control their environment, while accessing navigation, entertainment, and information hands-free. The personal assistant supports five major European languages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200827005197/en/
New Honda e and Jazz Cars in Europe to Feature In-Car Voice Assistant (Photo: Business Wire)
Houndify voice AI includes patented Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to deliver unprecedented speed and accuracy in voice recognition and responses. The platform’s ability to understand context, such as the user’s location or previous queries, eliminates the need to repeat information and allows more natural conversations.
Through the power of Houndify’s voice AI, drivers and passengers can ask Honda Personal Assistant even the most complex questions, such as: “OK Honda, show me restaurants within five kilometers, except French and Japanese ones, that have Wi-Fi, have at least three stars, and are open past 10 pm.” Houndify’s ability to remember context allows for useful follow-up questions, such as “Does it have parking?” The natural language interface can proactively prompt for the next step, like directions to the destination. Deep navigation integration allows drivers to further the experience by asking questions such as, “Are there any convenience stores along the way?”
“Honda e is the first fully electric vehicle to feature Houndify’s voice AI platform, and Jazz is one of Honda’s most popular cars in Europe , ” said Keyvan Mohajer, CEO and co-founder of SoundHound Inc. “We are proud of our partnership with Honda Motor Company and look forward to the growing use of the Honda Personal Assistant in Europe.”
SoundHound Inc. and Honda Motor Company first announced their partnership in October 2018 and premiered their collaboration at the 2019 Tokyo Motor show, where they demonstrated the Honda Personal Assistant to positive reviews.
The voice-enabled Honda Personal Assistant is available on Honda e and select Honda Jazz models in French, German, Spanish, Italian, and English languages.
To learn more about Honda Personal Assistant, powered by Houndify, visit SoundHound Inc.’s Speech-to-Meaning blog.
Developers interested in exploring Houndify’s independent voice AI platform can visit Houndify.com to learn more and register for a free account.
About SoundHound Inc.:
SoundHound Inc. turns sound into understanding and actionable meaning. We believe in enabling humans to interact with the things around them in the same way we interact with each other: by speaking naturally to mobile phones, cars, apps, TVs, smart speakers, and every other part of the emerging ‘connected’ world. Our consumer app, Hound, leverages our Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to create a groundbreaking smartphone experience, and is the first product to build on the Houndify platform. Our SoundHound App applies our technology to music, enabling people to discover, explore, and share the music around them, and even find the name of that song stuck in their heads by singing or humming. Through the Houndify platform, we aim to bring voice-enabled AI to everyone and enable others to build on top of it. We call this Collective AI. Our Mission: Houndify everything.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005197/en/
Contact information
Michael Zagorsek
SoundHound Inc.
408-441-3270
mike@soundhound.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom